[A24-16] Quizartinib (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2024
Project no.:
A24-16
Commission:
Commission awarded on 01.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with newly diagnosed FLT3-ITD-positive acute myeloid leukaemia, in combination with standard cytarabine and anthracycline induction chemotherapy and standard cytarabine consolidation chemotherapy, followed by maintenance treatment with quizartinib as monotherapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A24-16